TWI612042B - 環烷衍生物及其使用 - Google Patents

環烷衍生物及其使用 Download PDF

Info

Publication number
TWI612042B
TWI612042B TW102104725A TW102104725A TWI612042B TW I612042 B TWI612042 B TW I612042B TW 102104725 A TW102104725 A TW 102104725A TW 102104725 A TW102104725 A TW 102104725A TW I612042 B TWI612042 B TW I612042B
Authority
TW
Taiwan
Prior art keywords
oxy
pyrazol
pyrimidin
benzenesulfonamide
methyl
Prior art date
Application number
TW102104725A
Other languages
English (en)
Chinese (zh)
Other versions
TW201339152A (zh
Inventor
篠塚剛
小林宏行
鈴木沙也加
田中教介
木本裕子
土門友紀
Original Assignee
第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 第一三共股份有限公司 filed Critical 第一三共股份有限公司
Publication of TW201339152A publication Critical patent/TW201339152A/zh
Application granted granted Critical
Publication of TWI612042B publication Critical patent/TWI612042B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW102104725A 2012-02-09 2013-02-07 環烷衍生物及其使用 TWI612042B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012-025754 2012-02-09
JP2012025754 2012-02-09
JP2012259122 2012-11-27
JP2012-259122 2012-11-27

Publications (2)

Publication Number Publication Date
TW201339152A TW201339152A (zh) 2013-10-01
TWI612042B true TWI612042B (zh) 2018-01-21

Family

ID=48947609

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102104725A TWI612042B (zh) 2012-02-09 2013-02-07 環烷衍生物及其使用

Country Status (30)

Country Link
US (3) US8889741B2 (cg-RX-API-DMAC7.html)
EP (2) EP2813491B1 (cg-RX-API-DMAC7.html)
JP (2) JP5997710B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140127238A (cg-RX-API-DMAC7.html)
CN (1) CN104185629B (cg-RX-API-DMAC7.html)
AU (1) AU2013218592B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014019478A2 (cg-RX-API-DMAC7.html)
CA (1) CA2864222C (cg-RX-API-DMAC7.html)
CO (1) CO7151511A2 (cg-RX-API-DMAC7.html)
CY (1) CY1118572T1 (cg-RX-API-DMAC7.html)
DK (1) DK2813491T3 (cg-RX-API-DMAC7.html)
ES (2) ES2613078T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161713T1 (cg-RX-API-DMAC7.html)
HU (2) HUE037048T2 (cg-RX-API-DMAC7.html)
IL (1) IL234014A (cg-RX-API-DMAC7.html)
IN (1) IN2014MN01577A (cg-RX-API-DMAC7.html)
LT (1) LT2813491T (cg-RX-API-DMAC7.html)
MX (1) MX349354B (cg-RX-API-DMAC7.html)
NZ (1) NZ628096A (cg-RX-API-DMAC7.html)
PH (2) PH12014501804B1 (cg-RX-API-DMAC7.html)
PL (1) PL2813491T3 (cg-RX-API-DMAC7.html)
PT (1) PT2813491T (cg-RX-API-DMAC7.html)
RS (1) RS55671B1 (cg-RX-API-DMAC7.html)
RU (1) RU2635354C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201404707VA (cg-RX-API-DMAC7.html)
SI (1) SI2813491T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201700053T1 (cg-RX-API-DMAC7.html)
TW (1) TWI612042B (cg-RX-API-DMAC7.html)
WO (1) WO2013118854A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201405801B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630204B (zh) * 2013-03-14 2018-07-21 第一三共股份有限公司 呼吸器官疾病用藥

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093716B (zh) 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
ES2586213T3 (es) * 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
HK1209100A1 (en) 2012-05-22 2016-03-24 基因泰克有限公司 N-substituted benzamides and their use in the treatment of pain
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
KR20150131233A (ko) 2013-03-14 2015-11-24 제넨테크, 인크. 치환된 트리아졸로피리딘 및 이의 사용 방법
WO2014144545A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10179767B2 (en) 2015-05-22 2019-01-15 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3356360A1 (en) 2015-09-28 2018-08-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
BR112018008448A2 (pt) 2015-11-06 2018-11-06 Daiichi Sankyo Company, Limited ?método para produzir um composto?
MA43304A (fr) 2015-11-25 2018-10-03 Genentech Inc Benzamides substitués utiles en tant que bloqueurs de canaux sodiques
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
US10246453B2 (en) 2016-05-20 2019-04-02 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
BR112019007763A2 (pt) * 2016-10-17 2019-07-02 Genentech Inc composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
ES2897998T3 (es) * 2016-10-27 2022-03-03 Bristol Myers Squibb Co Inhibidores de la acilsulfonamida del NaV1.7
RU2760303C2 (ru) * 2016-12-09 2021-11-23 Ксенон Фармасьютикалз Инк. Соединения бензолсульфонамидов и их использование в качестве терапевтических средств
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
BR112020005455A2 (pt) 2017-09-20 2020-09-24 Abm Therapeutics Corporation derivados de iminopirimidina cíclica como inibidores de cinase
AR114263A1 (es) * 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
KR102833674B1 (ko) 2018-06-13 2025-07-14 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
CN112638879B (zh) 2018-08-31 2024-06-18 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为治疗剂的用途
WO2020047312A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
EP3902544A1 (en) * 2018-12-26 2021-11-03 RaQualia Pharma Inc. Heterocyclic derivatives as nav1.7 and nav1.8 blockers
US20240241265A1 (en) * 2023-01-18 2024-07-18 Qualcomm Incorporated Virtual positioning signal measurements

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
CN102348697A (zh) * 2009-01-12 2012-02-08 辉瑞股份有限公司 磺酰胺衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
RU2007146769A (ru) * 2005-05-16 2009-06-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные и их применение в качестве модуляторов ионых каналов
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
WO2010035166A1 (en) 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
CA2804173C (en) * 2010-07-09 2015-01-13 Pfizer Limited Sulfonamide nav1.7 inhibitors
CA2804593C (en) * 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
JP5860045B2 (ja) 2010-07-09 2016-02-16 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
CN102348697A (zh) * 2009-01-12 2012-02-08 辉瑞股份有限公司 磺酰胺衍生物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630204B (zh) * 2013-03-14 2018-07-21 第一三共股份有限公司 呼吸器官疾病用藥

Also Published As

Publication number Publication date
SI2813491T1 (sl) 2017-02-28
US9845313B2 (en) 2017-12-19
IL234014A (en) 2017-09-28
CN104185629A (zh) 2014-12-03
AU2013218592A1 (en) 2014-09-18
US20140045862A1 (en) 2014-02-13
DK2813491T3 (en) 2017-02-13
IN2014MN01577A (cg-RX-API-DMAC7.html) 2015-05-08
HUE031450T2 (en) 2017-07-28
JP2017008093A (ja) 2017-01-12
TW201339152A (zh) 2013-10-01
PT2813491T (pt) 2017-02-10
CA2864222A1 (en) 2013-08-15
PL2813491T3 (pl) 2017-08-31
BR112014019478A2 (pt) 2019-05-28
SMT201700053B (it) 2017-03-08
EP2813491A1 (en) 2014-12-17
SMT201700053T1 (it) 2017-03-08
CO7151511A2 (es) 2014-12-29
JPWO2013118854A1 (ja) 2015-05-11
ES2613078T3 (es) 2017-05-22
JP5997710B2 (ja) 2016-09-28
ES2659434T3 (es) 2018-03-15
LT2813491T (lt) 2017-02-10
ZA201405801B (en) 2015-12-23
CN104185629B (zh) 2017-10-13
US9493448B2 (en) 2016-11-15
US8889741B2 (en) 2014-11-18
CY1118572T1 (el) 2017-07-12
MX349354B (es) 2017-07-24
NZ628096A (en) 2016-06-24
PH12014501804A1 (en) 2014-11-17
IL234014A0 (en) 2014-09-30
CA2864222C (en) 2016-10-25
HRP20161713T1 (hr) 2017-02-10
KR20140127238A (ko) 2014-11-03
RS55671B1 (sr) 2017-06-30
EP2813491A4 (en) 2015-08-12
AU2013218592B2 (en) 2016-12-22
US20150018551A1 (en) 2015-01-15
MX2014009637A (es) 2015-06-23
WO2013118854A1 (ja) 2013-08-15
EP3144300A1 (en) 2017-03-22
EP3144300B1 (en) 2017-12-20
HUE037048T2 (hu) 2018-08-28
RU2014136463A (ru) 2016-03-27
JP6154052B2 (ja) 2017-06-28
PH12015502675A1 (en) 2017-04-24
RU2635354C2 (ru) 2017-11-13
US20170001984A1 (en) 2017-01-05
EP2813491B1 (en) 2016-11-02
SG11201404707VA (en) 2014-10-30
PH12014501804B1 (en) 2014-11-17
HK1203503A1 (en) 2015-10-30

Similar Documents

Publication Publication Date Title
TWI612042B (zh) 環烷衍生物及其使用
TWI494317B (zh) 磺醯胺衍生物
CN115298170A (zh) 作为yap/taz-tead蛋白-蛋白相互作用抑制剂的联芳基衍生物
TWI606039B (zh) Ａｐｊ受體之三唑激動劑
TWI630204B (zh) 呼吸器官疾病用藥
TWI471132B (zh) ２－吡啶酮化合物
TW202039474A (zh) 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其組合物和方法
HK40087589B (zh) Cd38抑制剂
HK40087589A (zh) Cd38抑制剂
HK1161253B (en) Sulfonamide derivatives

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees